Ranibizumab (Lucentis) for the treatment of neovascular (wet) age-related macular degeneration

The conclusion on t=0 was that ranibizumab could be used for the treatment of minimally classic, predominantly classic and occult subfoveal neovascular AMD. Due to its greater efficacy and the improved quality-of-life, ranibizumab has an added therapeutic value compared to photodynamic therapy with verteporfin and treatment with pegaptanib.

This report is a summary of recommendations by Zorginstituut Nederland. The original text is in Dutch.